文献速递男科与性医学

长期睾酮治疗改善性腺功能减退男性的排尿、性功能及生活质量:倾向性匹配对照登记研究亚组结果

Long-Term Testosterone Therapy Improves Urinary and Sexual Function, and Quality of Life in Men with Hypogonadism: Results from a Propensity Matched Subgroup of a Controlled Registry Study.
PubMed 文献 · J Urol · 2017-07-18

该观察性前瞻性累积登记研究纳入656例总睾酮≤12.1 nmol/l且有性腺功能减退症状的男性,其中360例接受十一酸睾酮1000 mg/12周治疗最长10年,296例拒绝治疗者为对照;经倾向性匹配后每组各82例共164例。结果显示治疗组I-PSS、排尿后膀胱容量、AMS及IIEF-EF域均显著改善(各p<0.0001),而对照组未改善且排尿与勃起功能随随访恶化。

要点

  • 长期睾酮治疗组I-PSS与排尿后膀胱容量显著下降(各p<0.0001),对照组无变化。
  • 治疗组AMS与IIEF-EF域显著改善(p<0.0001),改善在随访全程维持。
  • 未治疗组排尿与勃起功能随随访持续恶化。

核心结论

  • 长期睾酮治疗使性腺功能减退男性的排尿功能、性功能及生活质量获得显著改善。
  • 未接受治疗的性腺功能减退男性排尿与勃起功能随随访持续恶化。

研究设计与样本

  • 观察性前瞻性累积登记研究,纳入656例平均±SD年龄60.7±7.2岁、总睾酮≤12.1 nmol/l且有性腺功能减退症状的男性。
  • 睾酮治疗组360例接受十一酸睾酮1000 mg/12周肠道外给药最长10年,296例拒绝睾酮治疗者为对照。
  • 每组各82例按年龄、腰围及体质指数进行倾向性匹配,共82对164例。
  • 数据分析时组间估计差异按代谢综合征组分及生活质量校正。

主要发现

  • 睾酮治疗组I-PSS与排尿后膀胱容量显著下降(各p<0.0001),未治疗组无此变化。
  • 睾酮治疗组AMS下降(p<0.0001),未治疗组无下降。
  • 睾酮治疗组IIEF-EF域显著改善(p<0.0001),未治疗组无改善。
  • 上述改善在随访全程维持。

关键数值与推荐

  • 总睾酮≤12.1 nmol/l且有性腺功能减退症状为纳入条件。
  • 十一酸睾酮剂量1000 mg/12周,肠道外给药,最长10年。
  • 倾向性匹配变量为年龄、腰围及体质指数,每组82例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We investigated the effects of long-term testosterone therapy on urinary and sexual function, and quality of life in hypogonadal men. MATERIALS AND METHODS: We performed an observational, prospective, cumulative registry study in 656 men with a mean ± SD age of 60.7 ± 7.2 years who had total testosterone 12.1 nmol/l or less and symptoms of hypogonadism. In the testosterone treated group 360 men received parenteral testosterone undecanoate 1,000 mg/12 weeks for up to 10 years. The 296 men who elected against testosterone therapy served as controls. From each group 82 patients were propensity matched by age, waist circumference and body mass index, resulting in 82 matched pairs of 164 men. Data were analyzed and estimated differences between the groups were adjusted for components of metabolic syndrome and quality of life. RESULTS: We found significant decreases in I-PSS (International Prostate Symptom Score) and post-void bladder volume (each p <0.0001) in patients receiving testosterone therapy but not in the untreated group. We recorded a decrease in AMS (Aging Males' Symptoms Scale) in the testosterone treated group but not in the untreated group (p <0.0001). We also recorded significant improvement in the IIEF-EF (International Index of Erectile Function-Erectile Function) domain in the testosterone treated group but not in the untreated group (p <0.0001). The improvement was maintained throughout followup. CONCLUSIONS: Long-term testosterone therapy in hypogonadal men resulted in significant improvements in urinary and sexual function, and in quality of life. In untreated hypogonadal men voiding and erectile function deteriorated with continued followup.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Haider KS, Haider A, Doros G, et al. Long-Term Testosterone Therapy Improves Urinary and Sexual Function, and Quality of Life in Men with Hypogonadism: Results from a Propensity Matched Subgroup of a Controlled Registry Study. J Urol. 2017. PMID: 28728990. doi:10.1016/j.juro.2017.07.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。